<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254462</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH066127</org_study_id>
    <secondary_id>K23MH066127</secondary_id>
    <nct_id>NCT00254462</nct_id>
  </id_info>
  <brief_title>Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children</brief_title>
  <official_title>Pharmacological Treatment of ADHD in Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of
      attention deficit hyperactivity disorder (ADHD) in young children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders in
      children. Children with ADHD often have impaired functioning in home and school and usually
      experience difficulty relating to peers. If left untreated, the disorder can have long-term
      adverse effects into adolescence and adulthood. Atomoxetine is a selective noradrenergic
      reuptake inhibitor that is FDA-approved for the treatment of ADHD in children, adolescents,
      and adults. Unlike most other medications for ADHD, atomoxetine is not a stimulant. Studies
      have shown that atomoxetine is effective in treating ADHD, but more information is needed on
      its effectiveness in young children. This study will evaluate the effectiveness of
      atomoxetine in reducing the symptoms of ADHD in young children.

      Participants in this double-blind study will be randomly assigned to receive either
      atomoxetine or placebo for 8 weeks. In addition, all children will receive parent training
      for the duration of the study. For the first 5 weeks, participants will report to the study
      site weekly for assessments of ADHD symptoms. Study visits will occur every other week for
      the remainder of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ADHD-IV Rating Scale Total Score</measure>
    <time_frame>Measured at baseline and at Week 8. These are the only two timepoints calculated, later timepoint subtracted from earlier timepoint.</time_frame>
    <description>Measures 18 symptoms of attention deficit hyperactivity disorder (ADHD). Each symptom rated 0-3, for a minimum total score of 0, and a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.
The inattentive subscale and the hyperactive/impulsive subscale each has a minimum score of 0 and maximum score of 27.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total ADHD-IV Teacher</measure>
    <time_frame>Measured at baseline and at Week 8. Later time point is subtracted from earlier time point.</time_frame>
    <description>Measures 18 symptoms of ADHD. Each symptom rated 0-3, for a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>atomoxetine and parent training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo and parent training</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.</description>
    <arm_group_label>atomoxetine and parent training</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.</description>
    <arm_group_label>placebo and parent training</arm_group_label>
    <other_name>Pill placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Parent Training</intervention_name>
    <description>All children will receive parent training for the duration of the study.</description>
    <arm_group_label>atomoxetine and parent training</arm_group_label>
    <arm_group_label>placebo and parent training</arm_group_label>
    <other_name>Psychosocial and educational intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent and child must be English speaking

          -  Child has been living with parent/guardian for at least six months

          -  Meets criteria for ADHD on the DISC, on clinical interview, and on clinical consensus
             conference

          -  ADHD is primary disorder with symptoms present for at least 9 months

          -  ADHD-IV-Rating Scale (ADHD-IV-RS)score that is at least 1.5 standard deviations above
             age and sex norms

          -  Score of 55 or below on the Children's Global Assessment Scale

          -  Score of 4 or greater on the Clinical Global Impression Scale

          -  Estimated Intelligence Quotient (IQ) of 70 or greater

          -  Currently participating in school at least 2 half-days per week

          -  Able to identify a teacher who can make valid assessments

          -  Patient and parent are able to attend regular study visits

        Exclusion Criteria:

          -  Currently taking other psychotropic medications or other medications with effects on
             the central nervous system

          -  Currently being treated effectively with atomoxetine

          -  Major medical conditions that might interfere with study medications

          -  History of or current clinically significant kidney illness

          -  Evidence of adjustment disorder, autism, psychosis, bipolar disorder, suicide
             ideations, or any other psychiatric disorder requiring treatment with additional
             psychotropic medication

          -  History of physical, sexual, or emotional abuse impacting clinical presentation

          -  Prior failure to respond to an adequate trial of atomoxetine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher J. Kratochvil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kratochvil CJ, Vaughan BS, Stoner JA, Daughton JM, Lubberstedt BD, Murray DW, Chrisman AK, Faircloth MA, Itchon-Ramos NB, Kollins SH, Maayan LA, Greenhill LL, Kotler LA, Fried J, March JS. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011 Apr;127(4):e862-8. doi: 10.1542/peds.2010-0825. Epub 2011 Mar 21.</citation>
    <PMID>21422081</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2005</study_first_posted>
  <results_first_submitted>October 3, 2011</results_first_submitted>
  <results_first_submitted_qc>June 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2013</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Christopher J. Kratochvil, M.D.</investigator_full_name>
    <investigator_title>Professor Psychiatry and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Atomoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in outpatient child psychiatry clinics at 3 academic institutions between October, 2005 and June 2008.</recruitment_details>
      <pre_assignment_details>The ADHD diagnosis was confirmed using standardized measures and cases were reviewed on conference calls by professionals from all 3 sites.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine</title>
          <description>Recommended dosing of once per day, with divided dosing allowed at investigators discretion. Maximum dose of 1.8 mg/kg/day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Recommended dosing of once per day, with divided dosing allowed at investigators discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine</title>
          <description>Recommended dosing once daily, divided dosing at investigator discretion. Maximum dose of 1.8 mg/kg/day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Recommended dosing once daily, divided dosing at investigator discretion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="0.6"/>
                    <measurement group_id="B2" value="6.1" spread="0.5"/>
                    <measurement group_id="B3" value="6.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ADHD-IV Rating Scale Total Score</title>
        <description>Measures 18 symptoms of attention deficit hyperactivity disorder (ADHD). Each symptom rated 0-3, for a minimum total score of 0, and a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.
The inattentive subscale and the hyperactive/impulsive subscale each has a minimum score of 0 and maximum score of 27.</description>
        <time_frame>Measured at baseline and at Week 8. These are the only two timepoints calculated, later timepoint subtracted from earlier timepoint.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Recommended dosing once daily, allowed to give in divided dose at investigator discretion. Maximum dose of 1.8 mg/kg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Recommended dosing once daily, allowed to give in divided dose at investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ADHD-IV Rating Scale Total Score</title>
          <description>Measures 18 symptoms of attention deficit hyperactivity disorder (ADHD). Each symptom rated 0-3, for a minimum total score of 0, and a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.
The inattentive subscale and the hyperactive/impulsive subscale each has a minimum score of 0 and maximum score of 27.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="1.7"/>
                    <measurement group_id="O2" value="-5.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total ADHD-IV Teacher</title>
        <description>Measures 18 symptoms of ADHD. Each symptom rated 0-3, for a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.</description>
        <time_frame>Measured at baseline and at Week 8. Later time point is subtracted from earlier time point.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Recommended dosing once daily, divided dose at investigator discretion. Maximum daily dose of 1.8 mg/kg/day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Recommended dosing once daily, divided dose at investigator discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total ADHD-IV Teacher</title>
          <description>Measures 18 symptoms of ADHD. Each symptom rated 0-3, for a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="1.7"/>
                    <measurement group_id="O2" value="-5.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine</title>
          <description>Recommended dosing once daily, divided dosing at investigator discretion. Maximum dose of 1.8 mg/kg/day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Recommended dosing once daily, divided dosing at investigator discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>gastrointestinal upset</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>aches/pains</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>affective flattening/blunting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>attention/hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>disruptive behavior</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>mood lability</sub_title>
                <counts group_id="E1" events="58" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" events="22" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatological</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study design does not allow differentiation between placebo response and psychoeducational treatment effect. Eight-week duration does not allow for examination of long-term effectiveness or assessment of adverse effects over time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christopher J. Kratochvil, M.D.</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-552-6005</phone>
      <email>ckratoch@unmc.ed</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

